Phase I Pharmacokinetic Study (BF-BLOCK) (BF-BLOCK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01423305
Recruitment Status : Completed
First Posted : August 25, 2011
Last Update Posted : October 21, 2011
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

Brief Summary:
The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.

Condition or disease Intervention/treatment Phase
Asthma Drug: Budesonide/formoterol capsule. Drug: Budesonide/formoterol capsule for oral adm. Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Charcoal on Gastrointestinal Absorption of Budesonide and Formoterol
Study Start Date : August 2011
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment A
Budesonide/formoterol capsule (Orion Pharma) for oral administration.
Drug: Budesonide/formoterol capsule.
Oral administration with concomitant charcoal.
Experimental: Treatment B
Budesonide/formoterol capsule (Orion Pharma) for oral administration.
Drug: Budesonide/formoterol capsule for oral adm.
Oral administration without concomitant charcoal.

Primary Outcome Measures :
  1. The evaluation of primary pharmacokinetic variable AUCt [ Time Frame: 4 weeks ]
    The evaluation of primary pharmacokinetic variable AUCt of this study will be based on statistical methods appropriate for crossover design.

Secondary Outcome Measures :
  1. Pharmacokinetic variables [ Time Frame: 4 weeks ]

  2. Pharmacokinetic variable [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy males and females aged 18-60 years.
  2. Normal weight at least 50 kg.

Exclusion Criteria:

  1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  3. Any condition requiring concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  4. Known hypersensitivity to the active substance(s) or the excipients of the drug.
  5. Pregnant or lactating females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01423305

Clinical Reseach Services Turku (CRST)
Turku, Finland, 20520
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Principal Investigator: Mika Scheinin, M.D.Ph.D Clinical Research Services Turku Finland

Responsible Party: Orion Corporation, Orion Pharma Identifier: NCT01423305     History of Changes
Other Study ID Numbers: 3103008
First Posted: August 25, 2011    Key Record Dates
Last Update Posted: October 21, 2011
Last Verified: October 2011

Keywords provided by Orion Corporation, Orion Pharma:

Additional relevant MeSH terms:
Formoterol Fumarate
Budesonide, Formoterol Fumarate Drug Combination
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Protective Agents